Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19981234 | 0.84 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL56405 | 0.84 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL6656473 | 0.83 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL29381145 | 0.83 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL166122 | 0.83 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL17916019 | 0.80 | TDP1 (0.50) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL6954298 | 0.79 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL4197298 | 0.79 | LMNA (0.56) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL9815347 | 0.79 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL22795141 | 0.79 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0229381-B1 | METHIONINE-SUBSTITUTED 1,4-DIHYDROPYRIDINES, PROCESS FOR THE PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0225574-B1 | NOVEL 1,4-DIHYDROPYRIDINES CONTAINING FLUORINE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1990-05-16 | — | — | EP | claimed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | claimed |
| EP-0229381-A1 | Methionine-substituted 1,4-dihydropyridines, process for the preparation and their use | BAYER AG (DE) | 1987-07-22 | — | — | EP | claimed |
| EP-0225574-A1 | Novel 1,4-dihydropyridines containing fluorine, process for their preparation and their use as medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | claimed |
| US-9585850-B2 | Methods of treatment using arylcyclopropylamine compounds | DUKE UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9452223-B2 | Materials and methods relating to glycosylation | GLYTHERA LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| EP-2442831-B9 | Materials and methods relating to glycosylation of a therapeutic polypeptide | GLYTHERA LTD (GB) | 2016-05-11 | — | — | EP | disclosed |
| EP-2442831-B1 | Materials and methods relating to glycosylation of a therapeutic polypeptide | GLYTHERA LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| US-20150258047-A1 | Therapeutic Compounds | AKTHELIA PHARMACEUTICALS (IS) | 2015-09-17 | — | — | US | disclosed |
| US-9078864-B2 | Agonists for antimicrobial peptide systems | AKTHELIA PHARMACEUTICALS (IS) | 2015-07-14 | — | — | US | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| EP-0229381-B1 | METHIONINE-SUBSTITUTED 1,4-DIHYDROPYRIDINES, PROCESS FOR THE PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-05-30 | — | — | EP | disclosed |
| EP-0225574-B1 | NOVEL 1,4-DIHYDROPYRIDINES CONTAINING FLUORINE, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | BAYER AG (DE) | 1990-05-16 | — | — | EP | disclosed |
| US-4808622-A | ANTIHYPERTENSIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-28 | — | — | US | disclosed |
| US-4798840-A | Coronary-active fluorine-containing 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1989-01-17 | — | — | US | disclosed |
| EP-0229381-A1 | Methionine-substituted 1,4-dihydropyridines, process for the preparation and their use | BAYER AG (DE) | 1987-07-22 | — | — | EP | disclosed |
| EP-0225574-A1 | Novel 1,4-dihydropyridines containing fluorine, process for their preparation and their use as medicaments | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | TDP1 750/4885LMNA 1125/4885CASP3 1442/4885 |
| US-20150258047-A1 | Therapeutic Compounds | VIP, CFTR, ATF1 | TDP1 4614/4885LMNA 4633/4885CASP3 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.